托瑞米芬

Toremifene (订货以英文为准)

编号:T126260
CAS号:89778-26-7
分子式:C26H28CLNO
分子量:405.96
货号 品牌 包装 目录价 您的价格 库存 数量 购买
T126260-25mg 阿拉丁 25mg ¥149.90
T126260-100mg 阿拉丁 100mg ¥477.90
T126260-500mg 阿拉丁 500mg ¥1599.90
产品名称 Toremifene
中文名称 托瑞米芬
CAS号 89778-26-7
分子式(M.F.) C26H28CLNO
分子量(M.W.) 405.96
储存条件 避光;-20°C储存;充氩
溶解性25°C: DMSO 120mg/mL ;Water <1mg/mL; Ethanol <1mg/mL
存贮条件储存温度-20°C
生化机理IC50 Value: 1±0.3μM. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis and other adverse effects resulting from ADT in men with prostate cancer [1]. in vitro: The growth of Ac-1 cells was inhibited by tamoxifen, toremifene and atamestane in vitro with IC50values of 1.8±1.3μM, 1±0.3μM and 60.4±17.2μM, respectively. The combination of toremifene plusatamestane was found to be better than toremifene or atamestane alone in vitro[2]. in vivo: The effect of this combination was then studied in vivo using Ac-1 xenografts grown in ovariectomized female SCID mice. The mice were injected with toremifene (1000μg/day), atamestane (1000μg/day), tamoxifen (100μg/day), or the combination of toremifene plus atamestane. In this study, our results indicate that the combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone[2]. Clinical trial: Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene[3].
搜索质检报告(COA)
搜索MSDS
相关产品
CAS号:40516-57-2
¥ 75.00 C826129-250mg
CAS号:72899-92-4
¥ 117.00 BD01089450-250mg
¥ 128.00 sh7651-500mL
¥ 128.00 sh8754-500mL
¥ 128.00 sh42798-500mL
CAS号:1611-83-2
¥ 180.00 27712B-5g
¥ 128.00 sh54098-500mL
¥ 1470.00 PAC489Hu01-100μl
CAS号:19455-79-9
¥ 688.00 C909708-25g